This post was originally published on this site
Quarterly core operating income rose to $4.08 billion, up from $3.96 billion a year earlier, the Swiss drugmaker said on Tuesday.
Quarterly revenues from arthritis and psoriasis drug Cosentyx gained 12% in constant currencies to $1.16 billion, slightly below-above analysts’ average forecast of $1.19 billion, based on Refinitiv data.
Revenues from heart failure treatment Entresto jumped 42% to $1.1 billion, surpassing the market consensus of $1 billion.
($1 = 0.9207 Swiss francs)
